1. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update

   • Shiv Kumar Sarin
   • Ashok Choudhury
   • APASL ACLF Research Consortium (AARC) for APASL ACLF working Party.

   Guidelines Open access 06 June 2019 Pages: 353 - 390

   

2. New treatment-induced adverse effects we need to learn as modern hepatologists

   • Yoshiyuki Ueno

   Invited Commentary 23 April 2019 Pages: 391 - 394

   

3. The first Chinese guidelines on the Management of Ascites and its Related Complications in Cirrhosis: a great goal for a great country

   • P. Angeli

   Commentary 16 July 2019 Pages: 395 - 398

   

4. Association of acute-on-chronic liver failure with vascular liver diseases

   • Akash Shukla
   • Abhinav Jain

   Point-of-View 07 June 2019 Pages: 399 - 402

   

5. Hepatology through the crystal ball

   • Roger Williams

   Review Article Open access 04 July 2019 Pages: 403 - 406

   

6. Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers

   • Tsutomu Nishida
   • Tokuhiro Matsubara
   • Masami Inada

   Review Article 09 July 2019 Pages: 407 - 415

7. Current status and perspectives for computer-aided ultrasonic diagnosis of liver lesions using deep learning technology

   • Naoshi Nishida
   • Makoto Yamakawa
   • Masatoshi Kudo

   Review Article 21 February 2019 Pages: 416 - 421

   

8. Pegylated-interferon consolidation treatment versus nucleos(t)ide analogue consolidation treatment in non-cirrhotic hepatitis B patients with hepatitis B e antigen seroconversion: an open-label pilot trial

   • Ying Zhou
   • Rong Yan
   • Hong Wang

   Original Article 06 June 2019 Pages: 422 - 430

   

9. Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection

   • Yu-Shan Huang
   • Hsin-Yun Sun
   • Chien-Ching Hung

   Original Article 08 June 2019 Pages: 431 - 439

   

10. CCN2–MAPK–Id-1 loop feedback amplification is involved in maintaining stemness in oxaliplatin-resistant hepatocellular carcinoma

    • Xia Liao
    • Yang Bu
    • Qingan Jia

    Original Article Open access 27 June 2019 Pages: 440 - 453

    

11. Alteration of splicing factors’ expression during liver disease progression: impact on hepatocellular carcinoma outcome

    • Hualin Wang
    • Bouchra Lekbaby
    • Patrick Soussan

    Original Article 28 May 2019 Pages: 454 - 467

    

12. Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis

    • Xiangbo Xu
    • Xiaozhong Guo
    • Xingshun Qi

    Original Article 07 June 2019 Pages: 468 - 481

    

13. Bacteroides in colonic mucosa-associated microbiota affects the development of minimal hepatic encephalopathy in patients with cirrhosis

    • Masafumi Haraguchi
    • Satoshi Miuma
    • Kazuhiko Nakao

    Original Article 09 July 2019 Pages: 482 - 489

    

14. Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular–clinical analysis and potential targeted approach

    • Keun Soo Ahn
    • Daniel O’Brien
    • Koo Jeong Kang

    Original Article 18 June 2019 Pages: 490 - 500

    

15. SHG/TPEF-based image technology improves liver fibrosis assessment of minimally sized needle biopsies

    • Bingqiong Wang
    • Yameng Sun
    • Hong You

    Original Article Open access 11 June 2019 Pages: 501 - 509

    

16. Biliary features in liver histology of children with autoimmune liver disease

    • Angelo Di Giorgio
    • A. D’Adda
    • L. D’Antiga

    Original Article 08 May 2019 Pages: 510 - 518